Modality
Small Molecule
MOA
GLP-1ag
Target
PD-L1
Pathway
RAS/MAPK
FTD
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Jul 2027
Phase 2Current
NCT04381496
2,652 pts·FTD
2020-05→TBD·Terminated
NCT06675914
233 pts·FTD
2021-01→2027-07·Recruiting
2,885 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-261.3y awayPh3 Readout· FTD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-07-26 · 1.3y away
FTD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04381496 | Phase 2/3 | FTD | Terminated | 2652 | eGFR |
| NCT06675914 | Phase 2/3 | FTD | Recruiting | 233 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |